ASCO 2022 | ctDNA sensitivity in early-stage disease

Name: ctDNA sensitivity in early-stage disease
Uploaded: 2022-06-05T00:00:00Z
Duration: 56 s
Description: Bruna Pellini, MD, Moffitt Cancer Center, Tampa, FL, discusses remaining challenges in implementing circulating tumor DNA (ctDNA)-based approaches in clinical practice, highlighting difficulties in detecting early-stage disease which may result in false negatives. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Bruna Pellini • 5 Jun 2022

ASCO 2022

General

Bruna Pellini, MD, Moffitt Cancer Center, Tampa, FL, discusses remaining challenges in implementing circulating tumor DNA (ctDNA)-based approaches in clinical practice, highlighting difficulties in detecting early-stage disease which may result in false negatives. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.